CTCharidimos Tzagarakis

Charidimos Tzagarakis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Charidimos Tzagarakis has a total of 87 co-authors. Here are the top co-authors by number of shared publications:

  • Giuseppe Pellizzer

    Department of Neuroscience, University of Minnesota, Minneapolis, MN, United States

    5 shared publications
  • Kâmil Uğurbil

    Center for Magnetic Resonance Research, Department of Radiology, University of Minnesota Medical School, Minneapolis, USA

    5 shared publications
  • Trenton A. Jerde

    Brain Sciences Center, Veterans Affairs Medical Center (11B), Minneapolis, USA

    5 shared publications
  • Apostolos P. Georgopoulos

    The HLA and Chronic Diseases Research Groups, Brain Sciences Center, Department of Veterans Affairs Health Care System, Minneapolis, MN 55417, USA; Department of Neuroscience, University of Minnesota Medical School, Minneapolis, MN 55455, USA; Institute for Health Informatics, University of Minnesota Medical School, Minneapolis, MN 55455, USA

    4 shared publications
  • Pavlos Gourtzelidis

    Veterans Affairs Medical Center

    3 shared publications
  • Scott M. Lewis

    Brain Sciences Center, Veterans Affairs Medical Center (11B), Minneapolis, USA

    3 shared publications

Latest Publications

  • Open Access

    Placebo and nocebo effects in gambling disorder pharmacological trials: a meta-analysis

    by Konstantinos Ioannidis, Nathan T.M. Huneke, Jeremy E. Solly, Guilherme Fusetto Veronesi, Charidimos Tzagarakis, Valeria Parlatini, Samuel J. Westwood, Cinzia Del Giovane, David S. Baldwin, Jon E. Grant, et al.

    Background: Placebo and nocebo effects are widely reported across psychiatric conditions, yet have seldom been examined in the context of gambling disorder. Through meta-analysis, we examined placebo effects, their moderating factors, and nocebo effects, from available randomised, controlled pharmacological clinical trials in gambling disorder. Methods: We searched, up to 19 February 2024, a broad range of databases, for double-blind randomised controlled trials (RCTs) of medications for gambling disorder. Outcomes were gambling symptom severity and quality of life (for efficacy), and drop outs due to medication side effects in the placebo arms. Results: We included 16 RCTs (n = 833) in the meta-analysis. The overall effect size for gambling severity reduction in the placebo arms was 1.18 (95%CI 0.91–1.46) and for quality of life improvement was 0.63 (0.42-0.83). Medication class, study sponsorship, trial duration, baseline severity of gambling and publication year significantly moderated effect sizes for at least some of these outcome measures. Author conflict of interest, placebo run-in, gender split, severity scale choice, age of participants or unbalanced randomisation did not moderate effect sizes. Nocebo effects leading to drop out from the trial were observed in 6% of participants in trials involving antipsychotics, while this was less for other medication types. Conclusion: Placebo effects in trials of pharmacological treatment of gambling disorder are large, and there are several moderators of this effect. Nocebo effects were measureable and may be influenced by medication class being studied. Practical implications of these new findings for the field are discussed, along with recommendations for future clinical trials.


  • Open Access

    Pharmacological Management of Gambling Disorder: A Systematic Review and Network Meta-Analysis

    by Konstantinos Ioannidis, Cinzia Del Giovane, Charidimos Tzagarakis, Jeremy E Solly, Samuel J. Westwood, Valeria Parlatini, Henrietta Bowden-Jones, Jon E Grant, Samuele Cortese, Samuel R Chamberlain

    Background: Clinical guidelines remain unclear on which medications for gambling disorder are to be preferred in terms of efficacy and tolerability. We aimed to compare pharmacological treatments for gambling disorder in terms of efficacy and tolerability, using network meta-analysis (NMA). Methods: We searched, up to 19 February 2024, a broad range of databases, including MEDLINE, EMBASE, PsycINFO, PubMed, CINAHL, AMED, and the Cochrane Database of Systematic Reviews, ERIC and Web of Science (including Science Citation Index Expanded (SCI-EXPANDED), Social Science Citation Index (SSCI), Conference Proceedings Citation Index-Science (CPCI-S) and Conference Proceedings Citation Index-Social Science and Humanities (CPCI-SSH)) via Web of Knowledge and the WHO International Trials Registry Platform (including ClinicalTrials.gov ), for double-blind randomised controlled trials (RCTs) of medications for gambling disorder. Outcomes were gambling symptom severity and quality of life (for efficacy), and tolerability. Confidence in the network estimates was assessed using the CINeMA framework. We followed the PRISMA-NMA guidelines and pre-registered the protocol [CRD42022329520]. Outcomes: We included 22 RCTs in the systematic review and 16 RCTs (n = 977 participants) in the NMA. Compared with placebo, moderate confidence evidence indicated that nalmefene [Standardized Mean Difference (SMD): −0·86; 95% confidence interval (CI: −1·32,-0·41)] reduced gambling severity, followed by naltrexone [-0·42; −0·85, 0·01)]. Nalmefene [Odds Ratio (OR): 7·55; 95%CI: 2·24-25·41] and naltrexone (7·82; 1·26-48·70) had significantly higher dropout due to side effects (lower tolerability) compared with placebo. Naltrexone (SMD: −0·50; 95%CI: −0·85,-0·14) and nalmefene (−0·36; −0·72,-0·01) were more beneficial than placebo in terms of quality of life. Olanzapine and topiramate were not more efficacious than placebo. Interpretation: Nalmefene and naltrexone currently have the most supportive evidence for the pharmacological treatment of gambling disorder. Further clinical trials of novel compounds, and analysis of individual participant data are needed, to strengthen the evidence base, and help tailor treatments at the individual patient level. Funding: This study was supported by unrestricted grant funds to Professor Chamberlain held at the University of Southampton, originating from the NHS. Research in Context: Evidence before this study: Over the past few decades, there has been a substantial need for evidence-based pharmacological treatments of gambling disorder. However, the benefits and safety of medications trialled to treat gambling disorder remains debateable. Before planning this study, we searched PubMed on 01.06.2022 (and again on 16.03.2024 for any new evidence) for meta-analyses of randomised controlled trials (RCTs) of pharmacological treatments for gambling disorder, using the following syntax/search terms: gambling [tiab] AND meta-analy* [tiab]. We found two recent pairwise meta-analyses assessing the efficacy and tolerability of individual medications. However, we could not find any network meta-analysis (NMA) providing evidence on the comparative efficacy and tolerability of medications used for the treatment of gambling disorder. As NMAs have been successfully used to inform treatment approaches for other conditions, the lack of NMA of pharmacological treatments for gambling disorder is an important gap. Added value of this study: We conducted the first NMA of pharmacological treatments for gambling, based on state-of-the-art methodology for NMA. Our NMA represents the most comprehensive synthesis to date on the comparative efficacy and tolerability of pharmacological options to treat gambling disorder. Unlike previous systematic reviews and pairwise meta-analyses of head-to-head trials, we considered each treatment option separately (i.e., not as “class of medication”) and focused on clinically relevant outcomes – namely, the efficacy on gambling severity symptoms, tolerability and effects on the quality of life. We found that nalmefene and naltrexone currently have the most supportive evidence, in terms of clinical efficacy (reduction of gambling severity and improvement in quality of life), for the pharmacological treatment of gambling disorder, whereas olanzapine or topiramate had less or no supportive evidence. We also found that nalmefene and naltrexone were less well tolerated than placebo, which highlights the need for future clinical trials to broaden the evidence base. Implications of all the available evidence: Evidence from our NMA supports the use of nalmefene and naltrexone in adults with gambling disorder as the preferred first pharmacological choice for the management of gambling disorder. Our NMA should inform future guidelines and supplement clinical decision-making on the choice of treatment for adults with gambling disorder, along with available evidence on psychological options, evidence on cost-effectiveness, and patients’ preferences. Future studies should evaluate a broader range of pharmacological agents for the treatment of gambling disorder .Future research should also include individual patient data in NMA of gambling disorder medications, which will allow a wider and more reliable estimation of predictors of individual response.


  • Open Access

    Editorial: Neural mechanisms of impulsivity and compulsivity and their clinical and therapeutic corollaries

    by Charidimos Tzagarakis

    Editorial: Neural mechanisms of impulsivity and compulsivity and their clinical and therapeutic corollaries

  • Open Access

    Neural encoding of the reliability of directional information during the preparation of targeted movements

    by Charidimos Tzagarakis, Sarah West, Giuseppe Pellizzer

    Visual information about an upcoming target can be used to prepare an appropriate motor response and reduce its reaction time. However, when the anticipation is incorrect and the planned response must be changed, the reaction time is lengthened. Here, we investigated the brain mechanisms associated with the reliability and validity of visual information used for motor preparation. We recorded brain activity using magnetoencephalography (MEG) during a delayed reaching task in which a visual cue provided valid information about the location of the upcoming target with 50, 75 or 100% reliability. We found that reaction time increased as cue reliability decreased and that trials with invalid cues had longer reaction times than trials with valid cues. MEG channel analysis showed that beta-band power from left mid-anterior channels correlated with the reliability of the cue after cue onset but before target onset. This effect was source localized over a large motor-related cortical and subcortical network. In addition, during invalid-cue trials there was a phasic increase of theta-band power following target onset from left posterior channels, localized to the left occipito-parietal cortex. Furthermore, the theta-beta cross-frequency coupling between left mid-occipital and motor cortex also transiently increased before responses to invalid-cue trials. In conclusion, beta-band power in motor-related areas reflected the reliability of visual information used during motor preparation, whereas phasic theta-band activity signaled whether the target was at the expected location or not. These results elucidate mechanisms of interaction between attentional and motor processes. Significance Statement We used magnetoencephalography to investigate how the brain mechanisms preparing a motor response take into account the reliability of information about the upcoming location of a target to reach, and how these mechanisms adjust when that information turns out to be incorrect. We found that during the response preparation, the power of motor-related beta-band oscillations changed with the reliability of the visual information. In addition, we found that after the onset of the target the power of the left occipito-parietal theta-band signaled whether the prior information was correct or not. The pattern of activity of the beta-band and theta-band explain the pattern of latency of responses in the task, and demonstrate how attentional and motor processes interact.


  • Open Access

    The Degree of Modulation of Beta Band Activity During Motor Planning Is Related to Trait Impulsivity

    by Charidimos Tzagarakis, Andrew Thompson, Robert D. Rogers, Giuseppe Pellizzer

    Impulsivity is a prominent personality trait, and a key modulating component of neurologic and psychiatric disorders. How impulsivity is related to the brain mechanisms associated with action planning is poorly understood. Here we investigated the relation between impulsivity and the modulation of beta band oscillatory activity associated with action planning and execution. Given that beta power decreases during action planning and decreases further during action execution, we hypothesized that during planning the level of beta band power of more impulsive individuals would be closer to the level reached during execution than that of less impulsive individuals. This could explain the tendency to “jump the gun” (commission errors) in high impulsivity. To test this hypothesis, we recruited healthy volunteers (50 participants analyzed) and used the Barratt Impulsiveness Scale questionnaire to evaluate their impulsivity as high or low. We then recorded their brain neuromagnetic signals while they performed an instructed-delay task that induced different levels of action planning by varying the number of spatial cues, hence the uncertainty, about the location of the upcoming target. During the early cue period of the task, we found a posterior (source localized in the occipito-parietal areas) and a left fronto-central group of channels (source localized in the left sensorimotor areas) where beta power was modulated by number of cues, whereas during the late cue period only the left fronto-central group was modulated. We found that the decrease of relative beta band power during action planning in the left fronto-central group of channels was more pronounced in the high impulsivity group than in the low impulsivity group. In addition, we found that the beta band-mediated functional connectivity between the posterior and the left fronto-central groups of channels was weaker in the high impulsivity group than in the low impulsivity group during the early cue period. Furthermore, high impulsives made more commission and movement errors in the task than low impulsives. These results reveal neural mechanisms through which impulsivity affects action planning and open the way for further study of the role of beta band activity in impulsivity, especially in the context of disease and therapeutics.


  • Open Access

    Brain oscillatory activity during motor preparation: effect of directional uncertainty on beta, but not alpha, frequency band

    by Charidimos Tzagarakis, Sarah West, Giuseppe Pellizzer

    In time-constraint activities, such as sports, it is advantageous to be prepared to act even before knowing precisely what action will be needed. Here, we studied the relation between neural oscillations during motor preparation and amount of uncertainty about the direction of the upcoming target. Ten right-handed volunteers participated in a cued center-out task. A brief visual cue identified the region of space in which the target would appear. Three cue sizes were used to vary the amount of information about the direction of the upcoming target. The target appeared at a random location within the region indicated by the cue, and the participants moved a joystick-controlled cursor towards it. Time-frequency analyses showed phasic increases of power in low (delta/theta: 30 Hz) frequency-bands in relation to the onset of visual stimuli and of the motor response. More importantly in regard to motor preparation, there was a tonic reduction of power in the alpha (8-12 Hz) and beta (14-30 Hz) bands during the period between cue presentation and target onset. During motor preparation, the main source of change of power of the alpha band was localized over the contralateral sensorimotor region and both parietal cortices, whereas for the beta-band the main source was the contralateral sensorimotor region. During cue presentation, the reduction of power of the alpha-band in the occipital lobe showed a brief differentiation of condition: the wider the visual cue, the more the power of the alpha-band decreased. However during motor preparation, only the power of the beta-band was dependent on directional uncertainty: the less the directional uncertainty, the more the power of the beta-band decreased. In conclusion, the results indicate that the power in the alpha-band is associated briefly with cue size, but is otherwise an undifferentiated indication of neural activation, whereas the power of the beta-band reflects the level of motor preparation.


  • Top Cited Papers
    Open Access

    Neuropsychological testing of cognitive impairment in euthymic bipolar disorder: an individual patient data meta‐analysis

    by C. Bourne, Ö. Aydemir, V. Balanzá‐Martínez, E. Bora, S. Brissos, J. T. O. Cavanagh, L. Clark, Z. Cubukcuoglu, V. V. Dias, S. Dittmann, et al.

    Objective: An association between bipolar disorder and cognitive impairment has repeatedly been described, even for euthymic patients. Findings are inconsistent both across primary studies and previous meta‐analyses. This study reanalysed 31 primary data sets as a single large sample (N = 2876) to provide a more definitive view.Method: Individual patient and control data were obtained from original authors for 11 measures from four common neuropsychological tests: California or Rey Verbal Learning Task (VLT), Trail Making Test (TMT), Digit Span and/or Wisconsin Card Sorting Task.Results: Impairments were found for all 11 test‐measures in the bipolar group after controlling for age, IQ and gender (Ps ≤ 0.001, E.S. = 0.26–0.63). Residual mood symptoms confound this result but cannot account for the effect sizes found. Impairments also seem unrelated to drug treatment. Some test‐measures were weakly correlated with illness severity measures suggesting that some impairments may track illness progression.Conclusion: This reanalysis supports VLT, Digit Span and TMT as robust measures of cognitive impairments in bipolar disorder patients. The heterogeneity of some test results explains previous differences in meta‐analyses. Better controlling for confounds suggests deficits may be smaller than previously reported but should be tracked longitudinally across illness progression and treatment.


  • Reduced Subjective Response to Acute Ethanol Administration Among Young Men with a Broad Bipolar Phenotype

    by Sarah W Yip, Joanne Doherty, Judi Wakeley, Kate Saunders, Charidimos Tzagarakis, Harriet de Wit, Guy M Goodwin, Robert D Rogers

    Elevated lifetime prevalence rates of alcohol use disorders (AUDs) are a feature of bipolar disorder (BD). Individuals at-risk for AUDs exhibit blunted subjective responses to alcohol (low levels of response), which may represent a biomarker for AUDs. Thus, individuals at-risk for BD may exhibit low responses to alcohol. Participants were 20 unmedicated adult males who reported high rates of hypomanic experiences (bipolar phenotype participants; BPPs), aged 18 to 21 years, and 20 healthy controls matched on age, gender, IQ, BMI, and weekly alcohol intake. Subjective and pharmacokinetic responses to acute alcohol (0.8 g/kg) vs placebo administration were collected in a randomized, double-blind, cross-over, placebo-controlled, within-subjects design. BPP participants reported significantly lower subjective intoxication effects (‘feel high’: F=14.2, p=0.001; ‘feel effects’: F=8.1, p=0.008) across time, but did not differ in their pharmacokinetic, stimulant, or sedative responses. Paradoxically, however, the BPP participants reported significantly higher expectations of the positive effects of alcohol than controls. Our results suggest that unmedicated young males with previous hypomanic experiences exhibit diminished subjective responses to alcohol. These blunted alcohol responses are not attributable to differences in weekly alcohol intake, pharmacokinetic effects (eg, absorption rates), or familial risk of AUDs. These observations suggest that the dampened intoxication may contribute to the increased rates of alcohol misuse in young people at-risk for BD, and suggest possible shared etiological factors in the development of AUDs and BD.


  • Top Cited Papers
    Open Access

    Beta-Band Activity during Motor Planning Reflects Response Uncertainty

    by Charidimos Tzagarakis, Nuri F. Ince, Arthur C. Leuthold, Giuseppe Pellizzer

    It has been known for many years that the power of beta-band oscillatory activity in motor-related brain regions decreases during the preparation and execution of voluntary movements. However, it is not clear yet whether the amplitude of this desynchronization is modulated by any parameter of the motor task. Here, we examined whether the degree of uncertainty about the upcoming movement direction modulated beta-band desynchronization during motor preparation. To this end, we recorded whole-head neuromagnetic signals while human subjects performed an instructed-delay reaching task with one, two, or three possible target directions. We found that the reduction of power of beta-band activity (16–28 Hz) during motor preparation was scaled relative to directional uncertainty. Furthermore, we show that the change of beta-band power correlates with the change of latency of response associated with response uncertainty. Finally, we show that the main source of beta-band desynchronization was located in the peri-Rolandic region. The results establish directional uncertainty as an important determinant of beta-band power during motor preparation and indicate that neural activity in the sensorimotor cortex during motor preparation covaries with directional uncertainty.